Portal de Periódicos da CAPES

[First results with a new prostaglandin E2-derivate (author's transl)].

1977; National Institutes of Health; Volume: 37; Issue: 12 Linguagem: Inglês

M. Schmidt‐Gollwitzer, K. Schmidt-Gollwitzer, B. Schüßler, R. Koch, J Nevinny-Stickel,

Assisted Reproductive Technology and Twin Pregnancy

A new tissue-selective prostaglandin E2-derivate, 16-Phenoxy-prostaglandin E2-methansulfonamide (SH B 286) developed by Pfizer, USA, and Schering, Germany, has been investigated as abortifacient using the intrauterine as well as intravenous route of application. Vital signs, intrauterine pressure, serum levels of steroid hormones, hPL and hCG were recorded before, during and after administration of Pg SH B 286. By using 100--250 microgram Pg SH 286 extraamniotically abortion rates reached 80%. Severe systemic effects did not occur. Uterine cramps (40% of the women), nausea (23%) and vomitus (15%) were tolerable and needed rarely medication. The intravenous administration of Pg SH B 286 has been investigated for the first time with three dosis regimens. 33 of 38 women had complete abortion with dose-dependant side effects and without severe complications. The low dosage schedule (0,5--1,5 microgram/ml, total approx. 1000 microgram) had the same efficacy rate as the higher ones and was associated with the lowest systemic side effects. Premedication with analgetics was not necessary. Pg SH B 286 caused a marked increase of intrauterine pressure inducing abortion. If the measured decline of steroid hormones--mainly progesterone--contributes to the abortifacient efficacy of this prostaglandin is yet unsolved. The clinical usefulness of Pg SH B 286 has been demonstrated by our study.Use of 16-phenoxy-prostaglandin E2 methane sulfonamide (SH B 286), a prostaglandin E2 derivative, as an abortifacient in 114 patients is reported. Vital signs, intrauterine pressure, and blood levels of steroid hormones, chorionic gonadotropin, and placental lactogen were noted before, during, and after administration. Extraamniotic injection of 100-250 mcg induced abortion in 80% of the 76 women observed. No severe systemic effects occurred, and vomiting (15%), nausea (25%), and uterine cramps (40%) rarely required treatment. Of 38 women receiving an intravenous drip, complete abortion was induced in 33; side effects were dose-dependent and no severe complications were seen. The lowest dose (0.5-1.5 mcg/ml, 1000 mcg total dose) was as effective as larger doses. Uterine contractions were increased by the medication, while serum hormone levels, especially progesterone, decreased. SH B 286 is shown by this study to be an effective and safe abortifacient. (Author's)